Q-omics provides the consensus-scored TTC5 profile across patient tissues and cancer cell-line models. TTC5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TTC5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TTC5 RNA expression shows 21,159 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where TTC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC5 survival associations across molecular data types. TTC5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC5 RNA expression–survival associations across cancer types. High TTC5 expression shows unfavorable associations in BLCA, ACC, LIHC and LGG, but favorable associations in BRCA and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for TTC5 RNA expression.
This table summarizes TTC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC5 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, BLCA and COAD. The HNSC box plot shows higher TTC5 RNA expression in tumor versus normal tissue (log2 FC = +0.807, t-test p < 0.001).
This table shows molecular features associated with TTC5 in patient tissues and cancer cell lines. In patient samples, TTC5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
